-
Schedule Highlights from the Program Chairs: Wednesday, April 22
Don’t miss the final Plenary Sessions, Poster Sessions, and more, say Program Committee Chairs Paul S. Mischel, MD, FAACR, and Alice T. Shaw, MD, PhD, FAACR.
-
Third Clinical Trials Plenary Session delved into next-generation cellular therapies and immunotherapies
Omar Nadeem, MD, discussed results of the CAR-PRISM trial, which evaluated the use of ciltacabtagene autoleucel in patients with high-risk smoldering myeloma, an early, asymptomatic form of multiple myeloma.
-
Fourth Clinical Trials Plenary Session highlighted emerging developments in immunotherapy
Alberto Giovanni Leone, MD, shared results from cohort two of the single-arm, nonrandomized phase II INFINITY clinical trial assessing a combination treatment of tremelimumab and durvalumab.
-
Four novel molecules disclosed at the first New Drugs on the Horizon session
Presenters shared details from the forefront of translational innovation in oncology, highlighting for the first time the chemical structures and mechanisms of action of four novel therapeutic molecules—NEO-811, AZD8359, TNG961, and EPI-326.
-
Schedule Highlights from the Program Chairs: Tuesday, April 21
Don’t miss a Plenary Session on early-onset cancers, sessions on precision oncology and immunotherapy strategies, and more, say Program Committee Chairs Paul S. Mischel, MD, FAACR, and Alice T. Shaw, MD, PhD, FAACR.
-
Wednesday morning Plenary Session will examine innovative cancer treatment modalities
The first of two Plenary Sessions on Wednesday will convene leading experts who are advancing radioligand therapy, antibody-drug conjugates (ADCs), T‑cell engagers, and tumor‑infiltrating lymphocyte (TIL) therapy.
Meet the 2026 NextGen Stars
